A Phase 4 interventional study of Tranexamic Acid (TXA) in Healthy Participants, sponsored by University of British Columbia. Completed at 1 site in Canada. Open to female participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by University of British Columbia · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing Tranexamic Acid in Postpartum Hemorrhage — 8 open to participants now, 8 under way, 3 of them phase 3. Tranexamic Acid · Postpartum Hemorrhage.
Among the 50 studies testing Tranexamic Acid in Postpartum Hemorrhage, this one is the 34th largest by enrollment, is one of 4 that started in 2024, is one of 11 in phase 4, and was the 44th registered.
471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.
Browse Postpartum Hemorrhage studies →8 of the 50 studies testing Tranexamic Acid in Postpartum Hemorrhage are open now, in 8 countries. Recruiting first, the newest first:
Wolfson Medical Center · Sites in Israel
Ages 18–51 · Women only · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18–50 · Women only
Aligarh Muslim University · Sites in India
Ages 18–45 · Women only
London School of Hygiene and Tropical Medicine · Sites in Tanzania
Ages 18+ · Women only
Inova Health Care Services · Sites in United States
Ages 18–50 · Women only · Healthy volunteers
By country, each count listing its studies:
Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →
Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.
This study: 19 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 18 · Phase 4 11
First in 2009; this study’s year is marked. 4 started in 2024.
This study's enrollment of 110 is below the median of 148 across 362 interventional studies indexed under Postpartum Hemorrhage.
Median enrollment 198 across the 50 interventional studies. Of the 35 that completed or were terminated, 7 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 50 has an industry lead sponsor. The 10 most frequent:
University of British Columbia is the lead sponsor of 1,342 studies on the registry; 262 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
University of British Columbia has 2 studies filed under Postpartum Hemorrhage — fewer than ten, so there is no comparison to draw.
4 of the studies testing Tranexamic Acid in Postpartum Hemorrhage that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04304625Phase 3University Hospital, BordeauxTRAnexamic Acid for Preventing Blood Loss Following a Cesarean Delivery in Women With Placenta pREVIA | 2027-06 |
| NCT05562609Phase 3London School of Hygiene and Tropical MedicineTranexamic Acid to Prevent Heavy Bleeding After Childbirth in Women at Higher Risk | 2027-09 |
| NCT06754371RenJi HospitalProphylactic Tranexamic Acid Reduces Postpartum Hemorrhage | 2027-01 |
| NCT05370820Inova Health Care ServicesPrevention of Postpartum Hemorrhage With Tranexamic Acid | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 50 studies testing Tranexamic Acid in Postpartum Hemorrhage, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Tranexamic acid is a well-established treatment for post-partum hemorrhage. This study aims to examine the effect of tranexamic acid administration rates on blood pressure changes over 1 minute compared to 10 minutes in healthy pregnant patients scheduled for cesarean delivery.
Women who are clinically diagnosed with post-partum hemorrhage during a vaginal or cesarean delivery should be immediately administered tranexamic acid according to the World Health Organization's recommendation. Tranexamic acid is a drug that inhibits the breakdown of fibrin clots which reduces blood loss. However, due to the risk of hypotension, the product monograph for TXA advises against rapid intravenous (IV) administration. Other clinical studies have also reported an increased incidence of nausea, vomiting, and visual disturbances; nonetheless, the results of these trials suggest that these side effects may be related to properties of TXA rather than the rate of administration. Therefore, the investigators of this study aim to determine if the rate of tranexamic acid administration has an effect on blood pressure in healthy pregnant patients who are scheduled for cesarean delivery under spinal anesthesia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group will be administered tranexamic acid over 1 minute
Drug: Tranexamic Acid (TXA)
This group will be administered tranexamic acid over 10 minutes
Drug: Tranexamic Acid (TXA)
Study drug administration
Also known as: Tranexamic Acid
Change in systolic blood pressure from baseline over 15 minutes post-TXA administration between groups.
Change in systolic blood pressure from baseline over 15 minutes post-TXA administration between study and control groups
Time frame: 15 minutes starting from the time of completed TXA administration.
Incidence of nausea
sensation of self-reported nausea documented every 5 minutes.
Time frame: Up to 4 hours from time of TXA administration until time of discharge from the recovery room
Incidence of vomiting
vomiting documented every 5 minutes.
Time frame: Up to 4 hours from time of TXA administration until time of discharge from the recovery room
Incidence of hypotension
Incidence of systolic blood pressure reduction greater than or equal to 20% of baseline
Time frame: Up to 4 hours from time of TXA administration until time of discharge from the recovery room
Incidence of hypertension
Incidence of systolic blood pressure elevation greater than or equal to 20% of baseline
Time frame: Up to 4 hours from time of TXA administration until time of discharge from the recovery room
Incidence of central nervous system side effects
composite outcome of neurologic side effects including dizziness, headache, visual disturbances (photopsia) or facial flushing. These measures will be self-reported and documented every 5 minutes.
Time frame: Up to 4 hours from time of TXA administration until time of discharge from the recovery room
Plan to share: No
Ran from Mar 2024 to primary completion in Apr 2025, 13 months.
Of 28 non-industry phase 4 interventional studies under Postpartum Hemorrhage, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 13 months is close to that.
Counting every sponsor, half of 29 studies reached it within 12 months; a quarter within 10 and three quarters within 20.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Jul 2027 → Apr 2025 and completion Dec 2027 → Apr 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tranexamic Acid
University of British Columbia →